The creative collective disrupting healthcare communications for the better. Healthcare is one of the fastest changing industries on the planet. With Disruption® as our philosophy, TBWAWorldHealth ...

UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe ...

The fourth annual QiC Dermatology Awards took place in Reading earlier this month and results can be found online here: QiC ...

Join us for this episode of Global Health Beat, featuring Dr. Richard Bambury as he explores the unique opportunities for ...

Highly encouraged to read this in Jim Nantz voice Hello friends. Consider a brand. Picture an experience. The Masters, one of ...

Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...

Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to explore ...

More and more health data is being collected in the real-world about how that medicine works in a wider population than that ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s human medicines committee to treat younger eosinophilic oesophagitis (EoE) patients. The Committee ...

Ipsen’s Iqirvo (elafibranor) has been conditionally approved by the European Commission (EC) to treat primary biliary cholangitis (PBC). The oral peroxisome proliferator-activated receptor (PPAR) ...

Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients ...

Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for a subset of non-small cell lung cancer ...